• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Khosla Ventures Acquisition Co. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/12/23 4:03:53 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KVSA alert in real time by email
    8-K
    false 0001841873 --12-31 0001841873 2023-06-06 2023-06-06

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 6, 2023

     

     

    Khosla Ventures Acquisition Co.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40131   86-1488707

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    2128 Sand Hill Road

    Menlo Park, California

      94025
    (Address of Principal Executive Offices)   (Zip Code)

    (650) 376-8500

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Class A common stock, par value $0.0001 per share   KVSA   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 1.01

    Entry into a Material Definitive Agreement

    Amendment No. 1 to the Investment Management Trust Agreement

    As approved by its stockholders at the special meeting of stockholders held on June 6, 2023 (the “Special Meeting”), Khosla Ventures Acquisition Co., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company entered into Amendment No. 1 (the “IMTA Amendment”) to the Investment Management Trust Agreement, dated as of March 8, 2021 (the “IMTA”). The IMTA Amendment amends the IMTA allowing the Company to extend the period of time the Company must consummate a Business Combination (as defined in the IMTA) pursuant to the IMTA from June 8, 2023 to December 8, 2023.

    The foregoing description of the IMTA Amendment is qualified in its entirety by reference to the IMTA Amendment, a copy of which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

     

    Item 5.03

    Amendments to Articles of Incorporation or Bylaws

    As approved by its stockholders at the Special Meeting, the Company filed an amendment (the “Extension Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation (the “A&R Charter”) with the Secretary of State of the State of Delaware. The Extension Amendment extends the date by which the Company must consummate its initial business combination from June 8, 2023 to December 8, 2023.

    The foregoing description is qualified in its entirety by reference to the Extension Amendment, a copy of which is attached as Exhibit 3.1 hereto and is incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders

    On June 6, 2023, the Company convened the Special Meeting. As of the close of business on May 10, 2023, the record date for the Special Meeting, there were 35,490,000 outstanding shares of Class A common stock (“Class A common stock”), each of which entitles its holder to cast one vote per share with respect to the Extension Amendment Proposal and the Trust Amendment Proposal (each as defined below). There were also 5,000,000 outstanding shares of Class B common stock (“Class B common stock” and, together with the Class A common stock, the “Common Stock”), each of which entitles its holder to cast 1.217647 vote per share on an as converted basis with respect to the Extension Amendment Proposal and the Trust Amendment Proposal. A total of 30,086,860 shares of Common Stock, representing approximately 72.36% of the outstanding shares of Common Stock, on an as converted basis, entitled to vote at the Special Meeting, were present in person or by proxy, constituting a quorum. Additionally, a total of 6,039,529 shares of Class B common stock, representing approximately 99.2% of the outstanding shares of Class B common stock, on an as converted basis, entitled to vote at the Special Meeting, were present in person or by proxy, constituting a quorum solely with respect to the Extension Amendment Proposal. The proposals listed below are described in more detail in the Company’s definitive proxy statement, which was filed with the Securities and Exchange Commission on May 19, 2023. The stockholders of the Company voted on proposals to amend the A&R Charter to extend the date by which the Company must consummate a business combination (the “Extension Amendment Proposal”) and to amend the IMTA to extend the date by which the Company must consummate a business combination (the “Trust Amendment Proposal”). A summary of the voting results at the Special Meeting is set forth below:

    The Extension Amendment Proposal – To approve and amend the A&R Charter to extend the date by which the Company must consummate a business combination from June 8, 2023 to December 8, 2023.

     

    For

     

    Against

     

    Abstain

    29,580,291   473,695   32,874

     

    2


    The Trust Amendment Proposal – To approve and amend the IMTA allowing the Company to extend the period of time required to consummate a business combination from June 8, 2023 to December 8, 2023.

     

    For

     

    Against

     

    Abstain

    29,580,291   473,695   32,874

    Stockholders holding 33,570,544 shares of Class A common stock exercised their right to redeem such shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $343,677,676 (approximately $10.237 per share) will be withdrawn from the Trust Account to pay such redeeming holders.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d)     Exhibits.

     

    Exhibit
    No.

      

    Description of Exhibits

      3.1    Amendment to the Second Amended and Restated Certificate of Incorporation of the Company.
    10.1    Amendment No. 1 to the Investment Management Trust Agreement, dated June 6, 2023, entered into between the Company and Continental Stock Transfer & Trust Company.
    104    Cover Page Interactive Data File (embedded within Inline XBRL document).

     

    3


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Khosla Ventures Acquisition Co.
    Date: June 12, 2023     By:  

    /s/ Peter Buckland

        Name:   Peter Buckland
        Title:   Chief Financial Officer

     

    4

    Get the next $KVSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution

    MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up,

    12/4/23 5:38:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Mutually Agree to Terminate Business Combination Agreement

    BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately. Both parties decided to terminate the Business Combination based on current market conditions, particularly in the biot

    11/15/21 5:40:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Announce Additional PIPE Commitments

    BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.

    11/9/21 4:00:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    SEC Filings

    View All

    SEC Form 15-12G filed by Khosla Ventures Acquisition Co.

    15-12G - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/21/23 9:20:51 AM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/12/23 5:25:01 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.

    25-NSE - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    12/11/23 5:05:42 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/24 4:55:28 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/12/24 12:56:18 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Khosla Ventures Acquisition Co.

    SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/23 4:18:34 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Financials

    Live finance-specific insights

    View All

    Khosla Ventures Acquisition Co. Announces Planned Transfer of Listing to NYSE in Connection with its Proposed Business Combination with Valo Health

    BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co

    10/28/21 7:13:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care